Identifying biomarkers for cerebral amyloid angiopathy
PRIORITY (Enpowering Progression Risk of Cerebral Amyloid Angiopathy)
This study is trying to find new ways to diagnose and understand cerebral amyloid angiopathy better by looking at different tests and samples from people who might have this condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Academic / other |
| Locations | 1 site (Milano) |
| Trial ID | NCT06960538 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify clinical, neuroradiological, and biochemical biomarkers that can enhance early diagnosis and risk stratification for cerebral amyloid angiopathy (CAA). Conducted at the Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan, it will enroll patients over 18 years with possible or probable CAA, either symptomatic or asymptomatic. Participants will undergo clinical assessments and brain MRI at baseline and follow-ups, with cerebrospinal fluid and plasma biomarker analyses performed to develop a predictive model for better therapeutic decision-making. The study will last for 36 months and aims to clarify the pathogenic and prognostic aspects of CAA.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years with possible or probable symptomatic or asymptomatic cerebral amyloid angiopathy.
Not a fit: Patients with contraindications to MRI or lumbar puncture, or those unable to provide informed consent due to cognitive impairment, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early diagnosis and personalized treatment strategies for patients with cerebral amyloid angiopathy.
How similar studies have performed: While there have been studies on biomarkers in CAA, this specific approach focusing on a comprehensive dataset and machine learning is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients of either sex over 18 years of age; * patients with possible and probable symptomatic or asymptomatic CAA with or without histological demonstration (modified Boston criteria); * patients who have had at least one brain MRI. Exclusion Criteria: * patients who have contraindications to undergoing brain MRI (e.g., pacemaker, incompatible mechanical valves, claustrophobia); * patients who have contraindications to or refuse to undergo lumbar puncture; * patients who are unable to provide informed consent for the study due to aphasic or cognitive impairment; * patients who are pregnant or breastfeeding.
Where this trial is running
Milano
- Fondazione IRCCS Istituto Neurologico Carlo Besta — Milano, Italy (Recruiting)
Study contacts
- Study coordinator: Anna Bersano, MD
- Email: anna.bersano@istituto-besta.it
- Phone: + 39 02.23941
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.